XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
ICH Q3C is one of the most frequently cited guidance documents in CDER chemistry deficiency letters, and most CMC teams believe they have implemented it correctly because they know the Class 1, 2, and
View details →
Across hundreds of FDA Warning Letters issued to pharmaceutical manufacturers over the past five years, five quality system deficiency patterns appear with such regularity that they constitute a predictive model for where the next
View details →
Scale-up from kilogram to metric-ton synthesis is not a linear amplification. It is a process re-development exercise governed by physical chemistry — heat transfer coefficients that drop by a factor of 5–10 between a
View details →
Most pharmaceutical manufacturers have a process validation Stage 3 Continued Process Verification program on paper — and most of those programs are generating data that no one is analyzing, producing control charts that no
View details → There are two moments in LNP manufacturing where the drug product is made. The one that actually determines the physical attributes of the particles you will release into patients is the moment the ethanol
View details → Woodbine Products Company Inc., a Medina, Ohio manufacturer of over-the-counter topical and ethanol-based drug products, received FDA Warning Letter 320-26-107 on July 27, 2026, following a February 9–13, 2026 inspection of its 915 W.
View details → Thomas Brunner Hygiene GmbH, a manufacturer of over-the-counter (OTC) antiperspirant products in Albershausen, Germany, received FDA Warning Letter 320-26-106 on July 24, 2026 — issued not after an on-site inspection, but after FDA's review
View details →
On May 28, 2026, FDA's Center for Drug Evaluation and Research issued Warning Letter 320-26-81 to Jubilant HollisterStier General Partnership at its Kirkland, Quebec facility — and the two observations cited reveal a contamination
View details → On May 27, 2026, FDA issued Warning Letter 320-26-80 to Pharmathen International S.A., a sterile drug product manufacturer located in Sapes, Rodopi Prefecture, Greece (Facility Establishment Identifier — FEI 3009961173). Following an inspection conducted
View details → On June 30, 2026, the Food and Drug Administration (FDA) classified a nationwide recall of prednisoLONE Acetate Ophthalmic Suspension, USP, 1%, manufactured by Lupin Limited at its Pithampur (Indore), Madhya Pradesh facility in India
View details → Baxter International Inc. Recall — Cefazolin in Dextrose Injection: The Sterile Manufacturing System Failure Behind a Cardboard-Particulate Recall and What Every Fill-Finish Packaging Line Must Verify Now
View details → The FDA has classified a nationwide recall of eight Rohto Cooling Eye Drops products as Class II, covering 11,960,623 cartons — roughly 12.46 million bottles — sold at Walmart, CVS, Amazon, Kroger, and directly
View details → On August 4, 2026, Fresenius Kabi announced a voluntary nationwide recall to the user level of one lot of Morphine Sulfate Injection, USP, Simplist 2 mg/1 mL, after discovering that a MicroVault sealed and
View details → On August 5, 2026, Victory Medical Center Pharmacy of Austin, Texas, announced a voluntary nationwide recall to the patient level of certain lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials after pharmacy testing identified
View details →
On August 10, 2026, Fresenius Kabi announced a nationwide recall to the user level of one lot of Tyenne (tocilizumab-aazg) Injection, 400 mg/20 mL, after an internal investigation at the firm found the product
View details → On August 4, 2026, Novartis Pharmaceuticals Corporation initiated a recall of one lot of Diovan (valsartan) 160 mg tablets, 90-count bottles — lot AV5913C, expiration June 2027 — manufactured by Patheon Manufacturing Services LLC
View details → On August 5, 2026, Zydus Pharmaceuticals (USA) Inc. initiated a recall of one lot of Mirabegron Extended-Release Tablets, 25 mg, 30-count bottles — lot E408618, NDC 70710-1159-3, expiration November 30, 2026 — manufactured by
View details → On June 23, 2026, the Food and Drug Administration (FDA) classified Amgen Inc.'s recall of Corlanor (ivabradine) tablets — 5 mg and 7.5 mg, with 934,577 bottles of the 5 mg strength alone across
View details →